Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB | Zendy

Inoussa Zabsonre | Zendy; Sein Sein Thi | Zendy; Vivian Cox | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB

Author(s) -

Inoussa Zabsonre,

Sein Sein Thi,

Vivian Cox

Publication year - 2020

Publication title -

the international journal of tuberculosis and lung disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.103

H-Index - 110

eISSN - 1815-7920

pISSN - 1027-3719

DOI - 10.5588/ijtld.20.0226

Subject(s) - bedaquiline , medicine , regimen , tuberculosis , intensive care medicine , multiple drug resistance , donation , family medicine , drug resistance , surgery , pathology , economic growth , mycobacterium tuberculosis , microbiology and biotechnology , biology , economics

To improve the unsatisfactory treatment outcomes of multidrug-resistant TB (MDR-TB), it is essential we use new regimens based on newer drugs. To address challenges in the introduction of BDQ and the shorter treatment regimen (STR), the USAID has committed to support countries receiving BDQ (through the USAID/Janssen Bedaquiline Donation Program), with targeted short-term technical assistance (TA). Six MDR-TB clinical consultants were recruited and provided TA to 17 countries between 2017 and 2019. Building on other in-country support, this short-term TA proved instrumental in overcoming barriers, such as misconceptions about BDQ safety, inadequate clinical skills to manage patients and limited expansion plans to increase access to BDQ and the STR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research